Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBPR108 (Prusogliptin) in Type 2 Diabetes Mellitus
NCT04161430Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prusogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Change from baseline in Hemoglobin A1c at 24 weeks. Started Jan 2020; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04161430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161430.